Summary Oncogenic KRAS G12D (KRAS∗) is critical for the initiation and maintenance of
pancreatic ductal adenocarcinoma (PDAC) and is a known repressor of tumor immunity …

Pancreaticobiliary cancer, encompassing malignancies of both the pancreatic and biliary
tract, presents a formidable clinical challenge marked by a uniformly bleak prognosis. The …

Pancreatic cancer (PC) is a highly malignant digestive tract tumor, with a dismal 5-year
survival rate. Recently, cuproptosis was found to be copper-dependent cell death. This work …

Increasing evidence suggests that cancer progression is strongly influenced by host immune
response, which is represented by immune cell infiltrates. T-lymphocyte-based …

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest types of cancer and has
a 5-year survival of less than 8% owing to its complex biology. As PDAC is refractory to …

Pancreatic cancer is an aggressive malignancy with a 5-year survival rate of 13% that
remains refractory to current immunotherapies, such as chimeric antigen receptor (CAR) T …

An immune cell score (ICS) was introduced for predicting survival in pancreatic ductal
adenocarcinoma (PDAC). Few studies have compared different methods of evaluating …

Only a subset of patients with breast cancer responds to immune checkpoint blockade (ICB).
To better understand the underlying mechanisms, we analyze pretreatment biopsies from …

Abstract Purpose Tertiary lymphoid structures (TLSs) and CD8+ T-cells are potential
prognostic indicators for pancreatic ductal adenocarcinoma (PDAC). We established a novel …

As a significant contributor to cancer-related death, pancreatic cancer, as a recalcitrant
tumor, generally has an appalling prognosis that has not altered over many years. At the …